文献速递妇科

高危子宫内膜癌前哨淋巴结定位的前瞻性验证研究

A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2017-05-18

该前瞻性手术试验纳入高危子宫内膜癌(3级、浆液性、透明细胞、癌肉瘤)患者,比较前哨淋巴结(SLN)活检与完整盆腔及腹主动脉旁淋巴结清扫的敏感性、假阴性率和假阴性预测值。101例可评估患者中,SLN敏感性95%(19/20),假阴性率5%(1/20),假阴性预测值1.4%(1/71);未检出SLN时行侧方特异性淋巴结清扫可使假阴性率降至4.3%(1/23)。

要点

  • 高危子宫内膜癌患者SLN总体敏感性95%(19/20),假阴性率5%(1/20)。
  • 未检出SLN时行侧方特异性淋巴结清扫,假阴性率降至4.3%(1/23)。
  • SLN活检联合侧方特异性清扫是完整淋巴结清扫的合理替代方案。

核心结论

  • SLN活检联合未检出SLN时的侧方特异性淋巴结清扫,是高危子宫内膜癌完整淋巴结清扫的合理替代方案。

研究设计与样本

  • 前瞻性手术试验,纳入高危子宫内膜癌(3级、浆液性、透明细胞、癌肉瘤)患者,所有患者术前行PET/CT并术中行SLN活检后行淋巴结清扫。

主要发现

  • 至少检出1枚SLN者占89%(90例),双侧检出58%,单侧盆腔40%,仅腹主动脉旁2%。
  • 23例(23%)有≥1枚阳性淋巴结,其中20/23检出≥1枚SLN,19/20的SLN为阳性。
  • 仅1例患者双侧SLN阴性而最终病理非SLN阳性。
  • SLN总体敏感性95%(19/20),假阴性率5%(1/20),假阴性预测值1.4%(1/71)。
  • 未检出SLN时行侧方特异性淋巴结清扫,假阴性率降至4.3%(1/23)。

关键数值与推荐

  • 吲哚菁绿用于61%,蓝色染料用于28%,蓝色染料联合锝用于11%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sentinel lymph node (SLN) mapping continues to evolve in the surgical staging of endometrial cancer (EC). The purpose of this trial was to identify the sensitivity, false negative rate (FNR) and FN predictive value (FNPV) of SLN compared to complete pelvic and para-aortic lymphadenectomy (LAD) in women with high-risk EC. METHODS: Women with high-risk EC (grade 3, serous, clear cell, carcinosarcoma) were enrolled in this prospective surgical trial. All patients underwent preoperative PET/CT and intraoperative SLN biopsy followed by LAD. Patients with peritoneal disease on imaging or at the time of surgery were excluded. Patients were evaluable if SLN was attempted and complete LAD was performed. RESULTS: 123 patients were enrolled between 4/13 and 5/16; 101 were evaluable. At least 1 SLN was identified in 89% (90); bilateral detection 58%, unilateral pelvic 40%, para-aortic only 2%. Indocyanine green was used in 61%, blue dye in 28%, and blue dye and technetium in 11%. Twenty-three pts. (23%) had ≥1 positive node. In 20/23, ≥1 SLN was identified and in 19/20 the SLN was positive. Only 1 patient had bilateral negative SLN and positive non-SLNs on final pathology. Overall, sensitivity of SLN was 95% (19/20), FNR was 5% (1/20) and FNPV was 1.4% (1/71). If side-specific LAD was performed when a SLN was not detected, the FNR decreased to 4.3% (1/23). CONCLUSION: This prospective trial demonstrated that SLN biopsy plus side-specific LAD, when SLN is not detected, is a reasonable alternative to a complete LAD in high-risk endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Soliman PT, Westin SN, Dioun S, et al. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017. PMID: 28528918. doi:10.1016/j.ygyno.2017.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。